JPRN-UMIN000019075已完成未知
Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer - Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of another malignancy which could affect compliance with the protocol or interpretation of result of the study. 2. Previous systemic chemotherapy with irinotecan. 3. Uncontrolled arterial hypertension (e.g. >= 150 / >= 90 mmHg despite standard medical management) 4. Active infection requiring intravenous antibiotics at entry. 5. Serious illness or medical conditions. 6. Uncontrolled diarrhea which disrupt daily life despite fully medical management. 7. History of severe allergy or hypersensitivity for any drugs. 8. Moderate or large ascites or pleural effusion. 9. Chronic daily treatment with oral cortisteroid treatment. 10. Evidence of psychological disorder. 11. Symptomatic evidence of known central nervous system metastases or carcinomatous meningitis. 12. Daily treatment with atazanavir sulfate. 13. Pregnant or breastfeeding, or unwilling to practice contraception during the study. 14. Known acute or choric-active infection with HBV or HCV. 15. Any condition that suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study.
研究者
相似试验
进行中（未招募）
2 期
A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancerGastric cancer, early relapse, irinotecan, ramucirumabD013274Gastric cancerJPRN-jRCTs051190071YAMAGUCHI Toshifumi40
已完成
不适用
Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane.gastric cancerJPRN-UMIN000018606Kobe City Medical Center General Hospital18
已完成
2 期
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaGastric AdenocarcinomaGastro-esophageal Junction AdenocarcinomaNCT03141034Washington University School of Medicine40
进行中（未招募）
1 期
Ramucirumab plus Irinotecan / Leucovorin / 5-FU compared to Ramucirumab plus Paclitaxel in patients with advanced or metastatic gastric cancer who failed one prior chemotherapy - The Phase II/III RAMIRIS STUDYadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005171-24-DEInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest429
招募中
1 期
Ramucirumab plus Irinotecan / Leucovorin / 5-FU compared to Ramucirumab plus Paclitaxel in patients with advanced or metastatic gastric cancer who failed one prior chemotherapy - The Phase II/III RAMIRIS STUDYadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005171-24-ATInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest429